RIGL — RIGEL PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1034842 ·
Last close
$42.92
Market Cap
$808.18M
52W High
$52.61
52W Low
$24.95
ADV30
237,556
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 80,890,000 | 70,107,000 | 17,105,000 | 13,185,000 | 523,877,000 | 46,646,000 | 78,770,000 |
| Jun 2026 | 78,703,000 | 70,178,000 | 23,575,000 | 17,290,000 | 521,066,000 | 60,816,000 | 95,644,000 |
| Mar 2026 | 58,818,000 | 54,212,000 | 11,885,000 | 8,654,000 | 504,608,000 | 24,411,000 | 104,711,000 |
| Dec 2025 | 69,802,000 | 63,847,000 | 23,170,000 | 268,065,000 | 513,594,000 | 40,580,000 | 122,114,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$79,389,000
Investing CF
$-49,059,000
Financing CF
$-22,921,000
CapEx
—
Dividends Paid
—
Buybacks
$-4,251,000
EPS Diluted TTM
$16.32
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-997,097,000
Inventory
$14,367,000
Receivables
$56,041,000
ST Investments
$34,513,000
EBIT TTM
$91,381,000
Pretax Income TTM
$85,576,000
Interest Exp TTM
$5,805,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$288,212,992
EBITDA
$79,574,000
Free Cash Flow
$-13,774,625
Enterprise Value
$655,095,360
Total Cash
$99,305,000
Total Debt
$7,792,000
Shares Out
18,829,972
Trailing EPS
$16.07
Book Value
$23.64
ROE
109.2%
ROA
12.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 294,282,000 | 125,466,000 | 367,024,000 | 513,594,000 | 122,114,000 | 391,480,000 | 75,655,000 |
| Dec 2024 | 179,278,000 | 24,192,000 | 17,485,000 | 163,976,000 | 160,688,000 | 3,288,000 | 31,471,000 |
| Dec 2023 | 116,882,000 | -20,491,000 | -25,091,000 | 117,225,000 | 145,869,000 | -28,644,000 | -5,743,000 |
| Dec 2022 | 120,242,000 | -54,230,000 | -58,573,000 | 134,279,000 | 147,895,000 | -13,616,000 | -73,758,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$276,785,000
NetIncome TTM
$321,909,000
OpCashFlow TTM
—
Assets (Latest)
$521,066,000
Forward EPS
$4.94
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $35.00 · spot: $42.53 · call volume: 218 · put volume: 103Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IRWD | IRONWOOD PHARMACEUTICALS INC | $806.23M | $4.87 | — |
| ARDX | ARDELYX, INC. | $799.36M | $3.18 | — |
| COLL | COLLEGIUM PHARMACEUTICAL, INC | $793.98M | $25.55 | — |
| LXRX | LEXICON PHARMACEUTICALS, INC. | $792.52M | $1.78 | — |
| SNDX | Syndax Pharmaceuticals Inc | $828.26M | $9.20 | — |
News headlines (Yahoo Finance, 1h cache)
Rigel to Present at the Jefferies Global Healthcare Conference in London
2026-11-10 13:05 · Yahoo
Rigel Pharmaceuticals Q3 Earnings Call Highlights
2026-11-06 19:14 · Yahoo
Rigel Pharmaceuticals Inc (RIGL) (Q3 2026) Earnings Call Highlights: Record Product Sales of ...
2026-11-06 19:14 · Yahoo
Rigel (RIGL) Q3 2026 Earnings Call Transcript
2026-11-06 06:13 · Yahoo
Rigel Pharmaceuticals (RIGL) Misses Q3 Earnings Estimates
2026-11-06 00:00 · Yahoo
Rigel: Q3 Earnings Snapshot
2026-11-05 23:03 · Yahoo
Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition
2026-11-04 14:15 · Yahoo
Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results
2026-10-29 12:05 · Yahoo
Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026
2026-10-19 12:05 · Yahoo
Rigel Pharmaceuticals (RIGL) Stock Sees Fair Value Lift As Veppanu Launch Adds Growth Hope
2026-08-16 05:08 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.